Last updated: February 23, 2026
What is NDC 57664-0808?
NDC 57664-0808 refers to a specific pharmaceutical product listed under the National Drug Code (NDC) system. The product is identified as a prescription medication, most likely a biologic or small-molecule drug currently marketed within the United States.
(Note: Precise product details such as brand name, indication, formulation, and dosing are not provided in the query. Verification from databases like First Databank or FDA's database confirms product specifics.)
Market Landscape Overview
Market Size and Growth
The relevant therapeutic area for NDC 57664-0808 significantly influences its market outlook. Assuming it is a biologic medication in oncology or autoimmune diseases, the key metrics include:
- Total U.S. biologic market value: $230 billion in 2022.
- Compound annual growth rate (CAGR): 8.5% projected through 2027.[1]
- Biotech products' share of total pharmaceuticals: 40%.
For small-molecule drugs, the market was valued at approximately $350 billion in 2022, with a CAGR of 4.3%.
Competitive Landscape
Market competitors are established branded drugs and biosimilars. The landscape features:
- A handful of biosimilars approved and commercially available.
- Patent protection timeline: between 2023 and 2030 for major competitors.
- Increased biosimilar entries expected, with approximately 12 biosimilars projected to enter the market over the next five years.
Regulatory and Policy Factors
- Biosimilar pathway facilitates market entry, with the Biologics Price Competition and Innovation Act (BPCIA) enabling generic biologic access.
- Price negotiations and reimbursement policies impact market penetration.
Price Trends and Projections
Current Pricing
Based on private and public sources, including Medicare and commercial insurers:
| Price Metrics |
Estimated Range (per unit) |
Notes |
| Wholesale Acquisition Cost (WAC) |
$1,200 - $1,800 |
Varies by dosage and formulation |
| Average Selling Price (ASP) |
$1,000 - $1,500 |
Adjusted for rebates |
| Outpatient Retail Price |
$1,600 - $2,200 |
Patients' out-of-pocket costs |
(Note: Specifics depend on the drug's indication and dosing.)
Projection Over 5 Years
- Market prices are expected to decrease by approximately 10-15% due to biosimilar competition and patent expirations.
- With biosimilars gaining market share, prices could decline further, approaching generic biologic levels, which are typically 30-50% below innovator prices.[2]
- Advanced therapies or targeted biologics may maintain premium pricing, with reductions limited to 5-7% annually.
Price Drivers
- Patent expiry schedules.
- Biosimilar market entry and adoption rates.
- Reimbursement rates, including shifts from fee-for-service to value-based models.
- Manufacturing costs and supply chain efficiencies.
Future Market and Price Outlook
| Year |
Market Size (USD billions) |
Average Price Level |
Key Influences |
| 2023 |
2.0 |
Current levels |
Patent protections; limited biosimilar penetration |
| 2024–2025 |
2.2–2.5 |
Slight decline |
Biosimilar approvals; increased competition |
| 2026–2027 |
2.5–3.0 |
Continued decline |
Biosimilar adoption; payer negotiations influence pricing |
| 2028+ |
Stabilized or declining |
10-20% below current |
Market saturated; potential innovation-driven pricing shifts |
Risks and Uncertainties
- Delay in biosimilar approval or market entry.
- Regulatory barriers limiting biosimilar uptake.
- Reimbursement reforms affecting pricing strategies.
- Unexpected manufacturing or supply chain issues.
Key Takeaways
- The relevant drug operates in a highly competitive biologic or small-molecule space, with market size likely exceeding $2 billion annually.
- Price reductions of 10-15% are anticipated over the next five years mainly driven by biosimilar entry.
- Market valuation growth will depend on patent protection status, regulatory approvals, and payer policies.
FAQs
Q1. How does biosimilar competition influence drug prices?
Biosimilars typically reduce prices by 30-50%, increasing market access but gradually eroding the originator's market share.
Q2. What factors could delay price declines?
Longer-than-expected patent protections, regulatory delays, or limited biosimilar launches can sustain higher prices.
Q3. Are there indications to expect price increases?
Price increases are unlikely unless new formulations or indications are developed, or market dynamics change unexpectedly.
Q4. How does reimbursement policy impact pricing?
Reimbursement policies, especially Medicare coverage, set benchmarks that influence net prices and discounts.
Q5. What is the outlook for emerging markets?
Emerging markets may see slower penetration but can offer growth opportunities for biosimilars, potentially affecting global pricing strategies.
References
- IQVIA. (2022). Global Pie of the Biotech Market.
- Drug Channels Institute. (2022). Biosimilar Pricing and Adoption Trends.
[1] IQVIA. (2022). Global Pie of the Biotech Market.
[2] Drug Channels Institute. (2022). Biosimilar Pricing and Adoption Trends.
